



Feidhmeannacht na Seirbhíse Sláinte, Seirbhís Aisíocaíochta Cúraim Phríomhúil
Bealach amach 5, M50, An Bóthar Thuaidh, Fionnghlas
Baile Átha Cliath 11, D11 XKF3
Fón: (01) 864 7100 Facs: (01) 834 3589

Health Service Executive, Primary Care Reimbursement Service
Exit 5, M50, North Road, Finglas,
Dublin 11, D11 XKF3
Tel: (01) 864 7100 Fax: (01) 834 3589

Seán Canney, T.D.
Dáil Éireann,
Leinster House,
Kildare Street,
Dublin 2.

23rd October 2025

PQ: 53248/25

To ask the Minister for Health if she will investigate the potential cost of extending the availability of glucose monitors to persons with diabetes, other than type 1 diabetes, including type 2 and type 3c diabetes, with a view to extending the availability of monitors to this cohort of patients; and if she will make a statement on the matter. -Seán Canney

Dear Deputy Canney,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 53248/25), which you submitted to the Minister for Health for response.

The Health Information and Quality Authority (HIQA) Rapid Health Technology Assessment (HTA) of Continuous Glucose Monitoring (CGM) in Adults with Type 1 Diabetes Mellitus was published on 29th September 2023. The published document can be found at: [Rapid Health Technology Assessment of Continuous Glucose Monitoring in Adults with Type 1 Diabetes Mellitus | HIQA](#).

In line with the advice from HIQA and due to the budget impact associated with CGM sensors, the HSE established a single national reimbursement application system for all CGM sensors on the reimbursement list on 01/12/2023.

Reimbursement support for CGM sensors at this point in time is based on the HIQA HTA and is for patients with type 1 diabetes mellitus regardless of age, who have required insulin from the outset. Reimbursement does not extend to other cohorts such as people with type 2 diabetes who require insulin, or patients previously diagnosed with type 2 diabetes which is now classified as type 1 diabetes based on laboratory investigations such as C-peptide measurement or diabetes-specific autoantibodies. To date, a HTA of CGM sensors for people with type 2 diabetes mellitus or other types of diabetes excluded from the HTA referenced above, such as latent autoimmune diabetes in adults (LADA), type 3c diabetes, monogenic forms of diabetes etc. has not been undertaken. Therefore, there is limited information to

support the extension of reimbursement to this cohort, including cost-effectiveness assessment and budget impact of same.

An application for reimbursement support of CGM sensors can be submitted for any patient, and each application is reviewed centrally by the HSE-Medicines Management Programme (MMP) on a case-by-case basis.

Currently, under the reimbursement application system, reimbursement for CGM sensors is supported for patients with type 1 diabetes mellitus treated with insulin from the outset. There are difficulties in accurately forecasting the potential budget impact of extending reimbursement support to other specific cohorts of patients such as those with type 2 diabetes and type 3c diabetes.

There are approximately 46,000 individuals in receipt of insulin under the Community Drug Schemes. Extending reimbursement support to all patients in receipt of insulin alone would lead to expenditure in excess of €130 million annually on CGM sensors, based on current patterns of utilisation (more than double the existing annual spend on CGM sensors). While there remains the potential for continuing to generate efficiencies from a sustained increase in utilisation of the preferred CGM sensors in preference to non-preferred alternatives, these efficiencies would only cover a small proportion of the cost of this extension, and the provision of additional funding would be required.

To date a health technology assessment of CGM sensors for people with type 2 diabetes mellitus or type 3c diabetes has not been undertaken. Therefore, there is limited information to support the extension of reimbursement to this cohort, including cost-effectiveness and budget impact of same.

Yours sincerely,

Suzanne Doyle
Primary Care Reimbursement Service

The Health Service Executive operates the General Medical Services Scheme, which includes Medical Cards and GP Visit Cards, under the Health Act 1970, as amended. It has established a dedicated contact service for members of the Oireachtas specifically for queries relating to the status of Medical Cards and GP Visit Cards applications, which the Deputy / Senator may wish to use for an earlier response. Tel: 01-8647180 / email: Oireachtas.pcrs@hse.ie